A Study of Abicipar Pegol in Japanese Patients With Neovascular Age-related Macular Degeneration

• Status: Completed
• Trial end date: 2015-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a safety and efficacy study of abicipar pegol in patients with neovascular age-related macular degeneration to establish comparability between Japanese and non-Japanese.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Allergan
• Treatments: Ranibizumab

Criteria

Inclusion Criteria:

• Ethnically Japanese

• Diagnosis of wet age-related macular degeneration in at least 1 eye

• Best corrected visual acuity of 20/32 to 20/320 in the study eye and 20/200 or better in the fellow eye

Exclusion Criteria:

• Hypersensitivity, allergy, or anaphylactic reaction to iodine or shellfish

• Cataract or refractive surgery within the last 3 months

• History of vitrectomy